The impact of the COVID-19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study.
SARS-CoV-2
coronavirus disease-2019
hepatocellular carcinoma
liver cancer
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
revised:
09
11
2023
received:
10
08
2023
accepted:
10
11
2023
pubmed:
20
11
2023
medline:
20
11
2023
entrez:
20
11
2023
Statut:
aheadofprint
Résumé
Coronavirus disease 2019 emerged in December 2019 and spread worldwide. This study aimed to clarify the impact of the coronavirus disease 2019 pandemic on the diagnosis and treatment of hepatocellular carcinoma (HCC) in Japan. First, we collected the monthly numbers of HCC-related general medical practices from January 2019 to December 2021 at liver disease-specific medical institutions in Japan. Next, we collected individual clinical information from patients with newly diagnosed HCC during this period. There was a decrease in the number of HCC-related medical practices, including referrals, enhanced abdominal ultrasonography and radiofrequency ablation, in Japan's first state of emergency (SOE; April-May 2020) compared with 2019. Fewer patients were diagnosed with new HCC during the first SOE than before or after it. There was no difference in tumor diameter, number of tumors or Barcelona Clinic Liver Cancer stage between patients diagnosed before the first SOE and those diagnosed during or after the first SOE. The median waiting times for treatment of patients diagnosed during and after the first SOE were 31 and 37 days, which were significantly shorter and not longer than that of patients diagnosed before the first SOE (36 days), respectively. The number of HCC-related general medical practices decreased during the first SOE. However, the coronavirus disease 2019 pandemic did not lead to HCC progression by diagnostic delays or cause HCC treatment delays in Japan.
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : MHLW Research Program on Emerging and Reemerging Infectious Diseases
ID : JPMH21HA2011
Informations de copyright
© 2023 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.
Références
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/s0140-6736(20)30183-5
Terada M, Ohtsu H, Saito S, Hayakawa K, Tsuzuki S, Asai Y, et al. Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan. BMJ Open. 2021;11(6):e047007. https://doi.org/10.1136/bmjopen-2020-047007
Nakase H, Hayashi Y, Hirayama D, Matsumoto T, Matsuura M, Iijima H, et al. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). J Gastroenterol. 2022;57(3):174-184. https://doi.org/10.1007/s00535-022-01851-1
Hayashi Y, Wagatsuma K, Nojima M, Yamakawa T, Ichimiya T, Yokoyama Y, et al. The characteristics of gastrointestinal symptoms in patients with severe COVID-19: a systematic review and meta-analysis. J Gastroenterol. 2021;56(5):409-420. https://doi.org/10.1007/s00535-021-01778-z
Li D, Ding X, Xie M, Tian D, Xia L. COVID-19-associated liver injury: from bedside to bench. J Gastroenterol. 2021;56(3):218-230. https://doi.org/10.1007/s00535-021-01760-9
Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74(3):567-577. https://doi.org/10.1016/j.jhep.2020.09.024
Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159(2):768-771.e3. https://doi.org/10.1053/j.gastro.2020.04.064
Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatol. 2020;73(3):705-708. https://doi.org/10.1016/j.jhep.2020.05.013
Sarin SK, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-Elsalam S, et al. Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020;14(5):690-700. https://doi.org/10.1007/s12072-020-10072-8
Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020;14(5):612-620. https://doi.org/10.1007/s12072-020-10078-2
Nakase H, Wagatsuma K, Nojima M, Matsumoto T, Matsuura M, Iijima H, et al. Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey. J Gastroenterol. 2023;58(3):205-216. https://doi.org/10.1007/s00535-022-01949-6
Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, et al. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology. 2020;72(1):287-304. https://doi.org/10.1002/hep.31281
Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020;2(5):100169. https://doi.org/10.1016/j.jhepr.2020.100169
Lau G, Sharma M, Force AC-T. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020;14(4):415-428. https://doi.org/10.1007/s12072-020-10054-w
Collaborative C. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg. 2020;107:1440-1449. https://doi.org/10.1002/bjs.11746
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377-381. https://doi.org/10.1016/j.jbi.2008.08.010
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208. https://doi.org/10.1016/j.jbi.2019.103208
Pellino G, Spinelli A. How coronavirus disease 2019 outbreak is impacting colorectal cancer patients in Italy: a long shadow beyond infection. Dis Colon Rectum. 2020;63(6):720-722. https://doi.org/10.1097/dcr.0000000000001685
Xu Y, Liu H, Hu K, Wang M. Clinical recommendations on lung cancer management during the COVID-19 pandemic. Thorac Cancer. 2020;11(7):2067-2074. https://doi.org/10.1111/1759-7714.13498
Toyoda H, Huang DQ, Le MH, Nguyen MH. Liver care and surveillance: the global impact of the COVID-19 pandemic. Hepatol Commun. 2020;4(12):1751-1757. https://doi.org/10.1002/hep4.1579
Ponziani FR, Aghemo A, Cabibbo G, Masarone M, Montagnese S, Petta S, et al. Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: a web-based survey. Liver Int. 2021;41(9):2228-2232. https://doi.org/10.1111/liv.14998
Maeda H, Endo H, Yamamoto H, Miyata H, Munekage M, Taketomi A, et al. Effects of the COVID-19 pandemic on gastroenterological surgeries in 2020: a study using the National Clinical Database of Japan. Ann Gastroenterol Surg. 2023;7(3):407-418. https://doi.org/10.1002/ags3.12638
Hussain MRA, Hiebert L, Sugiyama A, Ouoba S, Bunthen E, Ko K, et al. Effect of COVID-19 on hepatitis B and C virus countermeasures: hepatologist responses from nationwide survey in Japan. Hepatol Res. 2022;52(11):899-907. https://doi.org/10.1111/hepr.13819
Kuzuu K, Misawa N, Ashikari K, Kessoku T, Kato S, Hosono K, et al. Gastrointestinal cancer stage at diagnosis before and during the COVID-19 pandemic in Japan. JAMA Netw Open. 2021;4(9):e2126334. https://doi.org/10.1001/jamanetworkopen.2021.26334
Miyo M, Mizushima T, Nishimura J, Hata T, Tei M, Miyake Y, et al. Impact of the COVID-19 pandemic on colorectal cancer surgery in Japan: clinical Study Group of Osaka University-A multicenter retrospective study. Ann Gastroenterol Surg. 2022;7(1):121-130. https://doi.org/10.1002/ags3.12616
Geh D, Watson R, Sen G, French JJ, Hammond J, Turner P, et al. COVID-19 and liver cancer: lost patients and larger tumours. BMJ Open Gastroenterol. 2022;9(1):e000794. https://doi.org/10.1136/bmjgast-2021-000794
Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. J Gastroenterol. 2019;54(4):367-376. https://doi.org/10.1007/s00535-018-1532-5
Nakano M, Yatsuhashi H, Bekki S, Takami Y, Tanaka Y, Yoshimaru Y, et al. Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Sci Rep. 2022;12(1):1517. https://doi.org/10.1038/s41598-022-05444-z
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. Hepatol Int. 2022;16(5):1150-1160. https://doi.org/10.1007/s12072-022-10358-z
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, et al. Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients: multicenter analysis. Liver Cancer. 2023;12(3):209-217. https://doi.org/10.1159/000527402